BamSEC and AlphaSense Join Forces
Learn More

Acceleron Pharma Inc

Formerly NASDAQ: XLRN
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.5
from 10-Q 4 pages Amendment to the Employment Agreement
12/34/56
EX-10.4
from 10-Q 4 pages Amendment to the Employment Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Amendment to the Employment Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Amendment to the Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment to the Employment Agreement
12/34/56
EX-10.1
from 10-Q 103 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[* * *]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Collaboration, License and Option Agreement by and Between Acceleron Pharma, Inc. and Celgene Corporation August 2, 2011 Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[* * *]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed
12/34/56
EX-10.22
from 10-K 9 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Performance-Based Restricted Stock Unit Award Agreement
12/34/56
EX-10.21
from 10-K 5 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.20
from 10-K 7 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.19
from 10-K 6 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.18
from 10-K 6 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.12
from 10-K 10 pages December 10, 2019 This Letter Agreement (“Agreement”) Sets Forth the Terms and Conditions of Your Employment With Acceleron Pharma Inc. (The “Company”)
12/34/56
EX-10.11
from 10-K 3 pages December 2, 2019 Base Pay Your Initial Salary Will Be at the Rate of $525,000 Per Year Less Applicable Legal Deductions, Payable in Accordance With the Regular Payroll Practices of the Company. Bonus Beginning in Fiscal Year 2020, You Will Be Eligible to Participate in the Company’s Bonus Plan With a Target of 40% of Your Yearly Compensation, Which Would Be Typically Paid in February 2021. You Are Not Eligible to Receive a Bonus for Performance in 2019. Equity
12/34/56
EX-10.10
from 10-K 10 pages June 5, 2019 This Letter Agreement (“Agreement”) Sets Forth the Terms and Conditions of Your Employment With Acceleron Pharma Inc. (The “Company”), as Amended and Restated as of the Date Set Forth Above
12/34/56
EX-10.1
from 10-Q 3 pages Via Email March 10, 2020 Celgene Corporation 86 Morris Avenue Summit, Nj 07901 Re: Clarification of Rights and Obligations Under the Sotatercept Agreement
12/34/56
EX-10.22
from 10-K 8 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Performance-Based Restricted Stock Unit Award Agreement
12/34/56
EX-10.21
from 10-K 5 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.19
from 10-K 5 pages Acceleron Pharma Inc. 2013 Equity Incentive Plan Non-Statutory Stock Option Agreement
12/34/56
EX-10.14
from 10-K 10 pages June 29, 2018 This Letter Agreement (“Agreement”) Sets Forth the Terms and Conditions of Your Employment With Acceleron Pharma Inc. (The “Company”)
12/34/56
EX-10.13
from 10-K 4 pages June 15, 2018 Base Pay Your Initial Salary Will Be at an Annual Rate of $465,000 Less Applicable Deductions, Payable in Accordance With the Regular Payroll Practices of the Company. Bonus
12/34/56